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Africa
Abstract
Introduction: The extraordinarily high incidence of HIV in sub-Saharan Africa led to the search for cofactor
infections that could explain the high rates of transmission in the region. Genital inflammation and lesions
caused by sexually transmitted infections (STIs) were a probable mechanism, and numerous observational
studies indicated several STI cofactors. Nine out of the ten randomized controlled trials (RCTs), however,
failed to demonstrate that treating STIs could lower HIV incidence. We evaluate all 10 trials to determine if
their design permits the conclusion, widely believed, that STI treatment is ineffective in reducing HIV
incidence.
Discussion: Examination of the trials reveals critical methodological problems sufficient to account for
statistically insignificant outcomes in nine of the ten trials. Shortcomings of the trials include weak exposure
contrast, confounding, non-differential misclassification, contamination and effect modification, all of which
consistently bias the results toward the null. In any future STI-HIV trial, ethical considerations will again
require weak exposure contrast. The complexity posed by HIV transmission in the genital microbial
environment means that any future STI-HIV trial will face confounding, non-differential misclassification and
effect modification. As a result, it is unlikely that additional trials would be able to answer the question of
whether STI control reduces HIV incidence.
Conclusions: Shortcomings in published RCTs render invalid the conclusion that treating STIs and other
cofactor infections is ineffective in HIV prevention. Meta-analyses of observational studies conclude that STIs
can raise HIV transmission efficiency two- to fourfold. Health policy is always implemented under
uncertainty. Given the known benefits of STI control, the irreparable harm from not treating STIs and the
likely decline in HIV incidence resulting from STI control, it is appropriate to expand STI control
programmes and to use funds earmarked for HIV prevention to finance those programmes.
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Abstract
Introduction: The extraordinarily high incidence of HIV in sub-Saharan Africa led to the search for cofactor infections that could
explain the high rates of transmission in the region. Genital inflammation and lesions caused by sexually transmitted infections
(STIs) were a probable mechanism, and numerous observational studies indicated several STI cofactors. Nine out of the ten
randomized controlled trials (RCTs), however, failed to demonstrate that treating STIs could lower HIV incidence. We evaluate all
10 trials to determine if their design permits the conclusion, widely believed, that STI treatment is ineffective in reducing HIV
incidence.
Discussion: Examination of the trials reveals critical methodological problems sufficient to account for statistically insignificant
outcomes in nine of the ten trials. Shortcomings of the trials include weak exposure contrast, confounding, non-differential
misclassification, contamination and effect modification, all of which consistently bias the results toward the null. In any future
STI-HIV trial, ethical considerations will again require weak exposure contrast. The complexity posed by HIV transmission in the
genital microbial environment means that any future STI-HIV trial will face confounding, non-differential misclassification and
effect modification. As a result, it is unlikely that additional trials would be able to answer the question of whether STI control
reduces HIV incidence.
Conclusions: Shortcomings in published RCTs render invalid the conclusion that treating STIs and other cofactor infections is
ineffective in HIV prevention. Meta-analyses of observational studies conclude that STIs can raise HIV transmission efficiency
two- to fourfold. Health policy is always implemented under uncertainty. Given the known benefits of STI control, the irreparable
harm from not treating STIs and the likely decline in HIV incidence resulting from STI control, it is appropriate to expand STI
control programmes and to use funds earmarked for HIV prevention to finance those programmes.
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Introduction
Genital inflammation, lesions and HIV shedding caused by
some sexually transmitted infections (STIs) are thought to
promote HIV transmission and acquisition. Numerous obser-
vational studies in sub-Saharan Africa provide corroboration
[114]. In the early 1990s, the first randomized controlled trial
(RCT) to test the hypothesis that improving treatment of STIs
reduces HIV incidence was conducted in Mwanza, Tanzania
[15]. It found HIV incidence in the treatment arm 38% lower
than among controls, but nine subsequent trials exami-
ning the hypothesis did not find statistically significant results
[1624].
A number of articles offer explanations for why the post-
Mwanza STI-HIV trials did not replicate Mwanza’s success.
One explanation is that STI control is less likely to affect HIV
incidence in mature epidemics [11,2531] or where STI
prevalence is low [12,27,32]. Moreover, reductions in risky
sexual behaviours among controls [24,29,33] and enhanced
prevention services to controls [11,29,33] likely eroded
differences in HIV incidence between the trials’arms.Most trials
were underpowered as a result of lower than anticipated
HIV incidence among participants [29]. Some trials might
have had adherence problems or incorrect dosages of tested
medication [11,29,32]. Most trials found few significant
differences in STI incidence or prevalence outcomes [32];
only two trials found statistically significant differences for
more than two STI outcomes [19,21]. All but one of the trials
did not fully capture the effect of STIs on HIV transmission and
instead measured only the effect of STIs on HIVacquisition [34].
Most trials addressing bacterial STIs could have been con-
founded by herpes simplex virus, HSV-2 [17,25,27,32,35].
Finally, in one community-based trial, a substantial share of
incident HIV infections came from partnerships with people
outside the community, whose treatment status was un-
known and were likely untreated; the resulting exposure
misclassification could have obscured the effects of interven-
tions on HIV incidence within the study communities [36]
(see also [37]).
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Some commentators maintain that the post-Mwanza trials
cast considerable doubt on the proposition that STI-control
programmes can reduce HIV incidence. Prominent exam-
ples include Gray and Wawer [32] and Larson, Bertozzi
and Piot [38], who conclude that funds earmarked for HIV
prevention should not be spent on STI control because it is
not yet certain that controlling STIs helps to prevent HIV. In
contrast, others downplay the post-Mwanza trials because of
their numerous shortcomings and argue that observational
studies already provide sufficient evidence to justify STI
control as HIV-prevention programming [11] (see also [29]).
This article analyses the 10 trials that examined the impact
of STI control on HIV incidence in sub-Saharan Africa dis-
cussed in previous reviews [11,29,31,32,39]. Our argument builds
on those reviews and other commentary [11,2535,3942]
but presents a more detailed evaluation of the design of the
10 STI-HIV trials than earlier works, drawing upon a substantial
literature on the methodology of RCTs [4354].
Discussion
We find that both design and implementation deficiencies
led to weak exposure contrast, confounding, non-differential
misclassification bias, contamination and effect modification
in the post-Mwanza STI-HIV trials.
Weak exposure contrast
An RCT tests whether differences between interventions (also
called exposures) in treatment and control arms produce
different outcomes. All of the post-Mwanza trials included
important interventions designed to reduce HIV incidence
that were identical in both arms. There were other interven-
tions that differed between treatment and control arms, but
all of the post-Mwanza trials delivered treatment and/or
other HIV-prevention services to control arms that led to
weak exposure contrast between arms, which made it difficult
to detect statistically significant differences in HIV incidence
between arms.
Before the Mwanza trial tested the hypothesis that
improved treatment of STIs could reduce HIV incidence, there
was the assumption of equipoise. The control communities in
Mwanza received no interventions until after the trial was
completed. Mwanza’s success, however, changed the ethical
calculus in the design of STI-HIV trials by providing evidence
that STI-control programmes could affect HIV incidence.
Given the serious harm from untreated STIs and the apparent
impact on HIV incidence, ethics required that future trial
designs incorporate treatment of identified STIs plus other
interventions to reduce risk for all participants. Thus, the weak
exposure contrast in the post-Mwanza trials was dictated by
ethical considerations.
Because the ability of trials to find significant results
depends on differences in interventions, we organize our
discussion of the trials according to the interventions tested
(i.e. those differing between treatment and control arms).
Previous reviews [11,29,31] categorized the trials by level of
randomization (assignment of individuals vs. communities to
treatment or control arms) and whether trials tested bacterial
or viral STIs. Those approaches take the focus away from
the interventions and thus away from the weak exposure
contrast, which in our view is the central problem of the post-
Mwanza trials. As noted above, some commentary on the
trials mentions weak exposure contrast (without using the
phrase) as one of many problems, but none thoroughly
explores the issue. (Table 1 provides detail about the trials’
interventions and explains our names for them.)
Seven trials testing differences in medication or examination
regimens
In the Nairobi trial, participants in the treatment group were
given antibiotics presumptively each month. Controls visited a
clinicmonthly andwere treated for symptomatic bacterial STIs.
Moreover, every six months, all participants were screened,
examined and treated for symptomatic and asymptomatic
bacterial STIs [21].
In Abidjan, treatment group participants were examined for
STIs monthly. Controls reporting STI symptoms at monthly
visits were examined. In both arms, bacterial STIs diagnosed
by examination were promptly treated [20]. Every six months,
laboratory tests were used to screen all participants for STIs,
and all diagnosed bacterial STIs were treated.
Rakai [18] tested different ways of administering antibiotics
for STIs every 10 months: mass drug administration (MDA) in
the treatment-arm communities versus referring sympto-
matic controls for free treatment in mobile clinics present
in the community at the time of testing (and to government
clinics if positive for syphilis). MDA is sometimes understood
as a community-level intervention because its objective is to
reduce population prevalence. The community protection
occurs, however, because individuals with the target infection
are treated, not because uninfected individuals are treated.
Although randomization in the trial was at the community
level and there were identical community-level interventions
in the two arms (for example, free condom distribution
at various sites in the community), the interventions that
differed between arms  presumptive medication or referral
for treatment  were applied to individuals. Those interven-
tions differed between arms to the extent that individuals
in the control arm were non-compliant or asymptomatic.
Because many STIs are asymptomatic and probably not
everyone sought the treatment to which they were referred,
the trial’s interventions had different effects on STI prevalence
and incidence in treatment and control communities. Never-
theless, in Rakai as in all of the post-Mwanza trials, controls
received important interventions that weakened exposure
contrast and help explain the inability to find statistically
significant results.
Rakai-Maternal [19] project staff tested all participants for
syphilis, medicating positive treatment-arm participants and
referring positive controls to government clinics. Project staff
administered antibiotics to all treatment-arm participants and
to all controls with symptomatic bacterial STIs other than
syphilis. Interventions differed between arms because asymp-
tomatic bacterial STIs other than syphilis were not treated
among controls (assuming individuals referred for syphilis
treatment complied).
All three acyclovir trials (NW-Tanzania, 3-City and 14-City)
tested the difference between presumptive treatment with
daily doses of acyclovir to suppress HSV-2 ulceration versus
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Table 1. Description of STI-HIV trials
Name of triala
Location(s)
Lead author, date
Population Treatment-arm interventions Control-arm interventions
Trials in which the tested interventions were applied to communities
Mwanza
Mwanza, Tanzania
Grosskurth [15], 1995
Six matched pairs of
communities randomly
assigned to treatment
or control
Efforts to improve delivery of STI treatment
services, including establishment of STI
reference clinic, training health centre staff,
supervisory visits to clinics, stocking clinics
with STI drugs and providing information on
STIs to the community
Interventions in both arms
Baseline and follow up interviews and examinations in sample (N  1000) in each community
Everyone interviewed treated by clinician for symptomatic bacterial STIs and other illnesses
STI treatment in existing primary health care clinics
Masaka
Masaka, Uganda
Kamali [16], 2003
18 rural communities
randomly assigned to
Treatment Arm A,
Treatment Arm B or
control arm
A and B communities: information,
education and communication activities
B communities: efforts to improve STI
treatment by training health care workers in
syndromic management of STIs and stocking
clinics with STI drugs
Community development activities (such
as technical help and supervision for self-
support and for-profit groups) and general
health-related activities (such as home-
based care for the elderly and health
promotion seminars)
Interventions in both arms
Social marketing of condoms and voluntary counselling and testing for HIV
Zimbabwe-East
Manicaland, Zimbabwe
Gregson [17], 2007
Six matched pairs of
communities randomly
assigned to treatment
or control
Peer education and condom distribution
among female sex workers and male clients
funded by microfinance projects
Programmes to strengthen STI treatment in
government clinics, including stocking STI
medications
Open days at health centres with activities
to promote behaviour change
Interventions in both arms
Distribution and social marketing of condoms
AIDS awareness meetings, posters and leaflets
Syndromic STI treatment in government clinics
Trials in which the tested interventions were applied to individuals or couples
Rakai
Rakai, Uganda
Wawer [18], 1999
All consenting residents
aged 15 to 59 in 10
community clusters,
which were randomly
assigned to treatment
or control and visited
every 10 months
Presumptive treatment with azithromycin,
ciprofloxacin and metronidazole
 Intramuscular penicillin for serologically
identified syphilis; treatment in the home
within 24 hours of diagnosis
Those reporting STI symptoms referred for
free treatment in mobile clinics providing
general health care in the village at the time
of the visit
Presumptive treatment with antihelminthics
and nutritional supplements
Those with positive syphilis serology referred
to government clinics for free treatment
Interventions in both arms
Community education programmes for HIV prevention, counselling, free condoms and free health
care at mobile clinics present in village at time of household visits
Those with STI symptoms between visits advised to seek treatment at government clinics
Stillwaggon E and Sawers L. Journal of the International AIDS Society 2015, 18:19844
http://www.jiasociety.org/index.php/jias/article/view/19844 | http://dx.doi.org/10.7448/IAS.18.1.19844
3
Table 1 (Continued )
Name of triala
Location(s)
Lead author, date
Population Treatment-arm interventions Control-arm interventions
Rakai-Maternal
Rakai, Uganda
Presumptive treatment with azithromycin,
cefixime and metronidazole by project staff
Symptomatic bacterial STIs treated
syndromically at time of survey by project staff
Gray [19], 2001
All consenting pregnant
women in 10
community clusters,
which were randomly
assigned to treatment
or control and visited
every 10 months
(nested in the Rakai
trial [18])
 Intramuscular penicillin for serologically
identified syphilis by project staff
Those with positive syphilis serology referred
to government clinics for free treatment
Presumptive administration of nutritional
supplements
Interventions in both arms
Health education, condom promotion, HIV-prevention counselling and free health care at mobile
clinics
Those with STI symptoms between visits advised to seek treatment at government clinics
Abidjan
Abidjan, Coˆte d’Ivoire
Ghys [20], 2001
Female sex workers
(N542) attending STI
screening facility
randomly assigned to
treatment or control
Monthly clinic visits with examination,
testing for STIs and syndromic treatment
Monthly clinic visits with examination for
STIs if reporting vaginal discharge, abdominal
pain or genital ulcer
Interventions in both arms
Every six months, examination and testing for STIs and HIV and treatment for all diagnosed
bacterial STIs
Monthly health education and free condoms
Nairobi
Nairobi, Kenya
Kaul [21], 2004
Female sex workers
(N466) randomly
assigned to treatment
or control
Monthly doses of azithromycin Monthly placebos
Interventions in both arms
Prompt treatment of any symptomatic bacterial STI at monthly visit
Screening and therapy for asymptomatic bacterial STIs every six months
HIV and STI prevention counselling and free condoms
NW-Tanzania
Mwanza, Shinyanga and
Tabora
Watson-Jones [22], 2008
Female food and
recreational facility
workers (N821) with
HSV-2, randomly
assigned to treatment
or control
Daily doses of acyclovir Daily placebos
Interventions in both arms
Blood testing every three months
Vaginal specimens taken at 6, 12, 24 and 30 months
Examination at 3, 9, 15, 21 and 27 months if symptomatic
Syndromic management of any symptomatic STIs and treatment of laboratory-confirmed STIs
STI- and HIV-prevention counselling, free treatment for minor medical conditions and free condoms
3-Citiesb
Johannesburg, Harare
and Lusaka
Celum [23], 2008
HSV-2 seropositive
women (N1358)
randomly assigned to
treatment or control
Daily doses of acyclovir Daily placebos
Interventions in both arms
Treatment of HSV-2 ulceration diagnosed at monthly visits with five-day course of acyclovir
Monthly visits (and examinations if STI symptoms reported) plus quarterly examinations for
diagnosis and treatment of STIs and HSV-2 ulceration
STI- and HIV-prevention counselling
Free condoms
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treatment with acyclovir if diagnosed with HSV-2 ulcers at
monthly [23,24] or quarterly [22] examinations. The 3-City
trial reported that 31% of controls were treated with
acyclovir during the trial [23]. All participants in both arms
were treated for bacterial STIs using the same diagnostic
procedures and medications.
The results of the seven STI-HIV trials with individual-level
interventions can be summarized as follows: the trials
demonstrate that presumptive STI treatment for the treat-
ment arm provides about the same level of protection against
HIV transmission as the state-of-the-art treatment of sympto-
matic STIs provided to the control arm when combined with
established HIV-prevention services provided to all trial
participants.
None of the seven trials provides any evidence that treating
STIs, whether presumptively or after diagnosis, is ineffective in
reducing HIV incidence. Nevertheless, most reports of the
trials and additional commentary written by authors of the
trials summarize the results with assertions to that effect,
without reference to the numerous interventions in the
control arms. One review of the trials writes that they
‘‘demonstrated unequivocally that herpes suppressive therapy
using a currently available treatment regimen was ineffective
in reducing the acquisition or transmission of HIV’’ [11].
One trial asserts that ‘‘daily acyclovir therapy did not reduce
the risk of transmission of HIV-1’’ [23]. Another says, ‘‘We
observed no effect of the STD intervention on the incidence of
HIV-1 infection’’ [18]. Again, ‘‘the results of this trial indicate
that . . . acyclovir at a dose of 400 mg twice daily is not a viable
public health intervention’’ [22]. Finally, ‘‘our results show that
suppressive therapy with standard doses of acyclovir is not
effective in reduction of HIV-1 acquisition’’ [23].
By taking the focus away from exposure contrast (compar-
isons between arms), these statements give the incorrect
impression that the trials provide evidence that interventions
to reduce STIs have no effect on HIV incidence. The trials,
however, could only show the difference in outcomes
between arms; the interventions in both treatment and
control arms could have been effective in reducing HIV
incidence or not. The lack of statistically significant differ-
ences in outcomes between arms cannot be construed as
evidence about the effect of STI treatment on HIV incidence
in either arm.
Three trials testing differences in community-level
interventions
The Mwanza trial implemented community-level interven-
tions to strengthen syndromic treatment of STIs in treat-
ment communities but not in control communities. Mwanza
was the only trial with substantial exposure contrast and
significant results.
The Zimbabwe-East trial had many important HIV-
prevention interventions that were identical in the two
arms. Interventions designed exclusively for the treatment
arm were as follows: (1) microfinance projects to fund peer
education and condom distribution, (2) programmes to
strengthen STI treatment in health centres, and (3) open
days at health centres with activities to promote behaviour
change. Deterioration of the Zimbabwean economy under-
mined the effectiveness of all three interventions, thus
weakening exposure contrast. Economic problems caused
the following: (1) cancellation of the microfinance pro-
gramme, (2) shortages of fuel and medicine that undermined
the programme to strengthen STI treatment in health centres
and (3) fewer than planned health centre open days [17].
Exposure contrast was further diminished by unrelated
organizations that sponsored peer-education programmes
and other HIV-prevention activities in control communities.
Moreover, in treatment communities, messaging by other
agencies conflicted with the messaging promoted by the
trial’s interventions [17].
Table 1 (Continued )
Name of triala
Location(s)
Lead author, date
Population Treatment-arm interventions Control-arm interventions
14-Cities
Fourteen cities in sub-
Saharan Africa
Celum [24], 2010
Discordant couples
(N3408) in which the
HIV-positive partner
was also HSV-2 positive
randomly assigned to
treatment or control
Daily doses of acyclovir Daily placebos
Interventions in both arms
Those who were diagnosed with HSV-2 in quarterly examinations and/or who reported symptoms
consistent with HSV-2 ulceration in monthly interviews were treated with five-day course of acyclovir
Quarterly examinations for diagnosis and treatment of STIs
STI- and HIV-prevention counselling
Referral for HIV-positive partners to clinics offering ART
Free condoms
aIn the literature, the trials are referred to in a variety of ways, according to the lead author, the site of the trial or the interventions. We use a
uniform, geographic designation to identify the trials. bTrial included men who have sex with men in Peru and the United States, who fall outside
the purview of this article.
STI, sexually transmitted infection.
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In Masaka, Quigley et al. found that some participants
attended meetings in neighbouring communities assigned to
a different arm [42]. That contamination reduced the trial’s
actual (in contrast to designed) exposure contrast. Neither
Quigley et al. nor Kamali et al. [16] report using statistical
methods that correct estimates of the trial’s results for
contamination.
Economic chaos in Zimbabwe-East and contamination in
Masaka weakened actual exposure contrast, but both trials
found that some interventions produced significantly lower
HIV incidence. In Zimbabwe-East, there were AIDS aware-
ness meetings in both arms. Among men who attended the
meetings, HIV incidence and reported unprotected sexual
encounters were 52 and 55% lower than among men who did
not (both significant at the 0.05 level) [17]. In Masaka, HIV
incidence among men (most of whom were in the treatment
arm but some of whom were controls) who attended infor-
mational meetings addressing HIV and STIs was 68% lower
than among those who did not (significant at the 0.045 level);
for women attending the meetings, HIV incidence was 65%
lower (significant at the 0.01 level) [42].
Confounding
It has been often noted that the high prevalence of HSV-2 may
have confounded the results of all the trials treating only
bacterial STIs [17,18,21,25,27,35]. Identifying confounders
depends on how the exposure is defined since a confounder
must be associated with both the exposure and the outcome.
If the exposure in the bacterial STI trials is just one or several
bacterial STIs, then HSV-2 is not a confounder unless one
posits that HSV-2 piggybacks on the other STIs (and is thus
related both to exposure and outcome). Alternatively, if the
exposure is the treatment intervention itself, that would also
mean HSV-2 cannot be a confounder in the bacterial STI trials.
More commonly, however, authors discussing the trials treat
sexual behaviour as the exposure [1,8,10,21,25,27,32] be-
cause HIV and STIs share a mode of transmission, thus
confounding the effects [25,32]. If sexual behaviour is
considered the exposure, confounding is more serious in
the STI-HIV trials than is generally understood. The trials and
discussions of confounding in the trials overlook viral STIs
other than HSV-2 that could have cofactor effects on HIV
transmission, for example human papilloma virus [55]. More
generally, just as any viral STI would confound the results of
any bacterial trial, any bacterial STI could confound the results
of the HSV-2 trials under the broader definition of exposure.
However the exposure is defined, what is important for
the trials is that several different STIs (both viral and
bacterial) are common in the population and none of the
trials measured the effect of treating both kinds. Both viral
and bacterial STIs are associated with higher risk of HIV. Even
if treating one kind of STI has a beneficial effect in reducing
risk of HIV acquisition or transmission, that effect is less likely
to be observable (statistically significant) because of the
effect of all the other STIs.
The STI-HIV trials pose another problem. Confounding
should be eliminated or reduced in an experiment (such as
an RCT) through randomization. The larger the number of
random assignments in an experiment, the more closely the
distribution of known and unknown risk factors in randomly
assigned arms will resemble each other, reducing bias from
confounding [48]. What matters, however, is not the number
of participants in the trial but the number of randomizations
[48, p143; 54, p993]. Half of the trials  Mwanza, Rakai, Rakai-
Maternal, Zimbabwe-East and Masaka  had between 5 and 12
random assignments. With so few randomizations, one cannot
rule out substantial confounding. Furthermore, it is likely
that multiple confounders acted in the same direction to
promote HIV transmission and bias trial results toward the
null.
Another way to reduce confounding is restriction of study
subjects. Restricting participants to persons with just one STI,
however, would have entailed costly testing and continued
surveillance beyond the means of the trials’ authors. Restric-
tion, moreover, cannot control for unknown (or unrecognized)
confounders [48, p142] and so imposes high information costs
on trials.
Microbial communities and genital health
Genital morbidities that are not sexually transmitted can also
affect HIV outcomes. Symptoms of STIs (ulceration, inflam-
mation, HIV shedding) that are considered mechanisms that
increase HIV transmission efficiency are also symptoms of
non-sexually-transmitted parasitic, bacterial and fungal geni-
tal infections that are highly endemic in all trial sites. Because
they are not related to the exposure that causes STIs (sexual
contact), they are not confounders. Nonetheless, they are
important because the complexity of the genital microbial
community generates substantial statistical noise in a trial
that seeks to test the effect of treating just one or a few
genital infections. Two of the ten trials reported that only
about half of genital ulcers were of STI origin: 49% in Rakai
[18] and 53% in Masaka [56]. Others have mentioned  but
without elaboration  that non-sexually-transmitted genital
morbidity could have reduced the post-Mwanza trials’ ability
to find significant results [32].
Approximately 125 million people in sub-Saharan Africa are
infected with Schistosoma haematobium [57], which is far
higher than estimates of bacterial STI prevalence in the region
(Table 1 in [58]) and about the same as estimates of HSV-2
(Tables 2 and 3 in [59]). S. haematobium larvae are trans-
mitted through skin contact with contaminated water [6062].
Sequelae include genital ulceration, inflammation, increased
HIV shedding and other serious morbidities. The STI trials
were all conducted in countries with a high burden of
schistosomiasis [63]. In one study, 60% of women with
S. haematobium infection had genital manifestations [64].
Four other studies reported 30 to 75% of women in endemic
areas had reproductive tract infections of schistosomiasis,
with infestation of worms and ova in the vagina, uterus,
vulva or cervix [65]. In a community in rural Zimbabwe, 46%
of women had genital lesions caused by schistosomiasis
[66,67]. Only a single STI-HIV trial [18] even mentions schisto-
somiasis (but without distinguishing between S. haema-
tobium and Schistosoma mansoni), and none administered
the antischistosomal drug, praziquantel.
Schistosomal ulceration has been associated with three-
and fourfold higher HIV prevalence in two studies [66,68].
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The magnitude of that effect is comparable to the effect of
STIs on HIV; three meta-analyses of observational studies find
that STIs raise the risk of HIV transmission between two- and
fourfold [11,13,14]. Given the high prevalence in sub-Saharan
Africa of S. haematobium infection, its population attribu-
table fraction for HIV in the region is likely to be substantial.
Some genital ulcers caused by abrasions become infected
with Streptococcus or Staphylococcus bacteria [56]. Ulcers
initially caused by bacterial or viral STIs or schistosomiasis
also can become superinfected with Strep or Staph, prevent-
ing healing despite treatment with antibiotics, acyclovir or
praziquantel. InMasaka, 18% of ulcers examined were positive
for Staph or Strep [56]. No other trial mentions such ulcers and
only two report using broad-spectrum antibiotics effective
against those bacteria [18,19].
Bacterial vaginosis is not generally transmitted sexually,
cannot be treated with the antibiotics typically used for STIs
and can be recurrent. Bacterial vaginosis has been shown to
increase risk of HIV acquisition by disrupting genital microbial
communities [6975]. Several of the STI-HIV trials reported
substantial prevalence of bacterial vaginosis among partici-
pants in both arms [18,19,2123] or in the district in which
the trial was conducted [15], but only two reported post-trial
prevalence of bacterial vaginosis significantly lower in the
treatment arm than among controls [18,19].
Genital fungal infections can also produce inflammation
and ulceration. The most common is candidiasis, which can
double women’s risk of acquiring HIV [10,76]. Only three
trials even mention fungal infections [18,20,21].
There are two consequences of the failure of the 10 trials to
target all genital infections that could enhance efficiency
of HIV transmission. First, it constitutes non-differential
misclassification (simply put, omitting important explanatory
variables), which can bias results toward the null. Second,
biological interaction between genital infections could result
in effect modification, potentially invalidating the statistical
tests used by the trials. The scope and direction of the dis-
tortion depend on the nature of the biological interaction, the
statistical model tested and the choice of outcome measures
[48, p2028]. Restriction of study subjects to those without
other genital morbidities could have improved the accuracy of
testing STI interventions, but again, it would have entailed a
time-consuming and costly search for eligible subjects. In sum,
the failure of the trials to account for the complex genital
environment in which sexual transmission of HIV occurs
further undermines confidence in the trials’ results [77].
Conclusions
The STI-HIV trials failed to show that efforts to control
symptomatic STIs are consistently effective in reducing HIV
incidence. That failure is not surprising given the weak
exposure contrast, confounding, non-differential misclassifi-
cation, contamination and effect modification, all of which
biased the trials’ results consistently toward the null. The
problem with the trials was primarily their design, not their
implementation.
There are two important reasons why additional STI-HIV
trials would have the same design flaws as the previous
trials. First, ethical considerations will continue to necessitate
minimal exposure contrast. Second, the purpose of an RCT is
to test the impact of a single factor. RCTs are especially suited
to tests such as drug trials when efficacy and side effects are
unknown. They are not generally suited to public health
interventions [52] where multiple diseases interact and
recovery exhibits hysteresis, including schistosomiasis lesions
in adult women and superinfections that are refractory to
treatment. There are multiple benefits from treating STIs and
other infections in the genital microbial community, but an
RCT is unlikely to identify statistically significant results due
to confounding, non-differential misclassification and effect
modification. Thus, we do not advocate more STI-HIV trials.
Before the STI-HIV trials were launched, STI treatment was
known to be efficacious (for STIs), with minimal side effects.
The results of the Mwanza trial confirmed the already widely
held belief that STI control almost surely slowed the spread
of HIV. Recent meta-analyses of observational studies provide
further corroboration [11,13,14]. The nine post-Mwanza trials
do not confirm that hypothesis, but neither do they offer any
basis for rejecting it, given the nature of statistical testing
and, more importantly, given their multiple design flaws
enumerated here. RCTs impose an unachievable standard of
proof on the possible contribution of STIs to the spread
of HIV.
The question that the trials were supposed to settle was a
policy decision about allocating relatively abundant HIV funds
for STI treatment, a critical but underfunded area of public
health in sub-Saharan Africa. The issue was thus primarily
political, not scientific. But public policy and science have
different goals and different evidentiary standards [53]. Public
policy is almost always forged in the absence of precise
information [52,53]. There is no reason to require the same
degree of certainty for policy decisions as for basic science or
clinical research, particularly when known benefits and side
effects favour implementation [52]. Neither science nor public
health is served by the paralysis caused by the post-Mwanza
trials. Observational studies provide adequate evidentiary
basis for allocating some of the relatively abundant funds
earmarked for HIV in sub-Saharan Africa to treat cofactor
infections that promote HIV transmission.
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